Education
About Us
Working with TipRanks
Follow Us
Kiniksa Pharmaceuticals (KNSA)
NASDAQ:KNSA
KNSA Stock Chart & Stats
$41.73
$0.18(0.88%)
At close: 4:00 PM EST
$41.73
$0.18(0.88%)
Day’s Range― - ―
52-Week Range$17.82 - $44.42
Previous CloseN/A
Volume84.12K
Average Volume (3M)404.82K
Market Cap
$3.16B
Enterprise Value$2.77B
Total Cash (Recent Filing)$352.10M
Total Debt (Recent Filing)$9.72M
Price to Earnings (P/E)93.1
Beta0.57
Next Earnings
Mar 03, 2026EPS Estimate
0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.23
Shares Outstanding45,161,020
10 Day Avg. Volume444,154
30 Day Avg. Volume404,816
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)3.22
Price to Sales (P/S)3.34
P/FCF Ratio55.59
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue4.62
Enterprise Value/Gross Profit8.76
Enterprise Value/Ebitda61.32
Forecast
1Y Price Target
$53.50Price Target Upside28.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)1.63
Revenue Forecast (FY)$884.75M
Bulls Say, Bears Say
Bulls Say
Commercial TractionAnalysts note Arcalyst's sustained commercial momentum driven by rising new patient enrollments, an expanding prescriber base, and longer treatment durations that support continued sales growth.
Market PenetrationAnalysts point to substantial upside because current prescriber adoption represents only a small fraction of the total addressable prescriber market, implying further growth as penetration deepens.
Pipeline Dosing AdvantageAnalysts highlight that KPL-387's potential for much less frequent dosing compared with Arcalyst could encourage patient preference and prescriber switching, supporting margin upside since KPL-387 is wholly owned.
Bears Say
Clinical And Regulatory RiskAnalysts caution that KPL-387 remains in clinical development, exposing the company to regulatory approval and trial execution risks before it can contribute meaningfully to revenue and profitability.
Development Timeline UncertaintyAnalysts warn that uncertain clinical development timelines for KPL-387 could delay any anticipated market switch and postpone related margin and earnings improvements.
Trial Outcome RiskAnalysts note that adverse clinical trial results or failure to demonstrate superior dosing benefits would undermine expectations for franchise extension and could materially reduce the stock's upside.
Kiniksa Pharmaceuticals News
KNSA FAQ
What was Kiniksa Pharmaceuticals’s price range in the past 12 months?
Kiniksa Pharmaceuticals lowest stock price was $17.82 and its highest was $44.42 in the past 12 months.
What is Kiniksa Pharmaceuticals’s market cap?
Kiniksa Pharmaceuticals’s market cap is $3.16B.
When is Kiniksa Pharmaceuticals’s upcoming earnings report date?
Kiniksa Pharmaceuticals’s upcoming earnings report date is Mar 03, 2026 which is in 49 days.
How were Kiniksa Pharmaceuticals’s earnings last quarter?
Kiniksa Pharmaceuticals released its earnings results on Oct 28, 2025. The company reported $0.23 earnings per share for the quarter, missing the consensus estimate of $0.324 by -$0.094.
Is Kiniksa Pharmaceuticals overvalued?
According to Wall Street analysts Kiniksa Pharmaceuticals’s price is currently Undervalued.
Does Kiniksa Pharmaceuticals pay dividends?
Kiniksa Pharmaceuticals does not currently pay dividends.
What is Kiniksa Pharmaceuticals’s EPS estimate?
Kiniksa Pharmaceuticals’s EPS estimate is 0.35.
How many shares outstanding does Kiniksa Pharmaceuticals have?
Kiniksa Pharmaceuticals has 45,161,020 shares outstanding.
What happened to Kiniksa Pharmaceuticals’s price movement after its last earnings report?
Kiniksa Pharmaceuticals reported an EPS of $0.23 in its last earnings report, missing expectations of $0.324. Following the earnings report the stock price went down -2.882%.
Which hedge fund is a major shareholder of Kiniksa Pharmaceuticals?
Currently, no hedge funds are holding shares in KNSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kiniksa Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$53.50 (28.21% Upside)
$53.50 (28.21% Upside)
Blogger Sentiment
Bullish
KNSA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 193.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.7%
Last 30 Days ▲ 13.1%
Last 30 Days ▲ 13.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
105.56%
12-Months-Change
Fundamentals
Return on Equity
7.39%
Trailing 12-Months
Asset Growth
28.28%
Trailing 12-Months
Company Description
Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
KNSA Company Deck
KNSA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong positive outlook for Kiniksa Pharmaceuticals with significant revenue growth, increased sales guidance, and a robust financial position. The company highlights the increased adoption of ARCALYST and its FDA Orphan Drug Designation for KPL-387. However, challenges remain with limited market penetration and increased operating expenses.View all KNSA earnings summariesKNSA Stock 12 Month Forecast
Average Price Target
$53.50
▲(28.21% Upside)
Technical Analysis
Beam Therapeutics
―
Disc Medicine
―
Harmony Biosciences Holdings
―
Centessa Pharmaceuticals
―
CG Oncology, Inc.
―
Ownership Overview
7.30% Insiders
13.53% Mutual Funds
40.97% Other Institutional Investors
28.02% Public Companies and Individual Investors